Angola vs Madagascar: Average cost of multi drug-resistant tuberculosis treatment
Angola
537 constant 2022 US$
in 2023
Madagascar
532 constant 2022 US$
in 2024
Angola rank
76th
Madagascar rank
77th
Average cost of multi drug-resistant tuberculosis treatment over time
- Angola
- Madagascar
How they compare
Angola currently reports 537 constant 2022 US$ against 532 constant 2022 US$ in Madagascar, a difference of 5 constant 2022 US$.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Angola ahead.
Angola ranks 76th and Madagascar ranks 77th of 92 countries.
Angola has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Angola | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,284 constant 2022 US$ | 1,509 constant 2022 US$ | 775.33 constant 2022 US$ | Angola |
| 2020s | 1,917 constant 2022 US$ | 644.75 constant 2022 US$ | 1,272 constant 2022 US$ | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Angola or Madagascar?
- Angola, at 537 constant 2022 US$ against 532 constant 2022 US$ in Madagascar as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Angola and Madagascar?
- 5 constant 2022 US$, with Angola ahead.
- How many years of comparable data are there for Angola and Madagascar?
- 7 years are reported by both, from 2017 to 2023.
- How do Angola and Madagascar rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Angola ranks 76th and Madagascar ranks 77th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.